Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Huntingtin Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 0:28
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Huntingtin (Huntington Disease Protein or HTT) – Pipeline Review, H2 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein or HTT) targeted pipeline therapeutics.

The report provides comprehensive information on the Huntingtin (Huntington Disease Protein or HTT), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693278-huntingtin-huntington-disease-protein-or-htt-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein or HTT) 
- The report reviews Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein or HTT) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein or HTT) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693278-huntingtin-huntington-disease-protein-or-htt-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Global Markets Direct Report Coverage 6 
Huntingtin (Huntington Disease Protein or HTT) Overview 7 
Therapeutics Development 8 
Huntingtin (Huntington Disease Protein or HTT) – Products under Development by Stage of Development 8 
Huntingtin (Huntington Disease Protein or HTT) – Products under Development by Therapy Area 9 
Huntingtin (Huntington Disease Protein or HTT) – Products under Development by Indication 10 
Huntingtin (Huntington Disease Protein or HTT) – Pipeline Products Glance 11 
Late Stage Products 11 
Early Stage Products 12 
Huntingtin (Huntington Disease Protein or HTT) – Products under Development by Companies 13 
Huntingtin (Huntington Disease Protein or HTT) – Therapeutics Assessment 15 
Assessment by Monotherapy/Combination Products 15 
Assessment by Mechanism of Action 16 
Assessment by Route of Administration 17 
Assessment by Molecule Type 19 
Huntingtin (Huntington Disease Protein or HTT) – Companies Involved in Therapeutics Development 21 
AFFiRiS AG 21 
Ionis Pharmaceuticals, Inc. 22 
Neurimmune Holding AG 23 
nLife Therapeutics, S.L. 24 
reMYND NV 25 
Shire Plc 26 
UniQure N.V. 27 
Voyager Therapeutics, Inc. 28 
Vybion, Inc. 29 
WAVE Life Sciences Ltd. 30 
Huntingtin (Huntington Disease Protein or HTT) – Drug Profiles 31 
AMT-130 – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Antisense Oligonucleotide to Inhibit HTT for Huntington’s Disease – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
Antisense Oligonucleotide to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
INT-41 – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
IONIS-HTTRx – Drug Profile 39 
Product Description 39 
Mechanism Of Action 39 
R&D Progress 39 
NI-302 – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
Vaccine to Target Huntingtin for Huntington’s Disease – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
VYHTT-01 – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
WVE-120101 – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
Huntingtin (Huntington Disease Protein or HTT) – Dormant Projects 46 
Huntingtin (Huntington Disease Protein or HTT) – Featured News & Press Releases 47 
Aug 24, 2016: Novel Gene Therapy Drug for Huntington Disease 47 
Jun 21, 2016: WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease 47 
Mar 22, 2016: uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease 48 
Jan 05, 2016: Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington Disease 48 
Jul 21, 2015: Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington’s Disease 49 
Nov 19, 2014: Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington’s Disease Signs And Symptoms 50 
Nov 12, 2013: Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic For Huntington’s Disease 51 
Sep 03, 2013: Vybion’s Huntington Drug Neutralizes Critical Disease Driver 52 
Oct 17, 2012: Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic For Huntington’s Disease At 2012 Annual Meeting Of Society For Neuroscience 53 
Appendix 55 
Methodology 55 
Coverage 55 
Secondary Research 55 
Primary Research 55 
Expert Panel Validation 55 
Contact Us 55 
Disclaimer 56

List of Tables 
Number of Products under Development for, H2 2016 8 
Number of Products under Development by Therapy Area, H2 2016 9 
Number of Products under Development by Indication, H2 2016 10 
Comparative Analysis by Late Stage Development, H2 2016 11 
Comparative Analysis by Early Stage Products, H2 2016 12 
Number of Products under Development by Companies, H2 2016 13 
Products under Development by Companies, H2 2016 14 
Assessment by Monotherapy/Combination Products, H2 2016 15 
Number of Products by Stage and Mechanism of Action, H2 2016 16 
Number of Products by Stage and Route of Administration, H2 2016 18 
Number of Products by Stage and Molecule Type, H2 2016 20 
Pipeline by AFFiRiS AG, H2 2016 21 
Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 22 
Pipeline by Neurimmune Holding AG, H2 2016 23 
Pipeline by nLife Therapeutics, S.L., H2 2016 24 
Pipeline by reMYND NV, H2 2016 25 
Pipeline by Shire Plc, H2 2016 26 
Pipeline by UniQure N.V., H2 2016 27 
Pipeline by Voyager Therapeutics, Inc., H2 2016 28 
Pipeline by Vybion, Inc., H2 2016 29 
Pipeline by WAVE Life Sciences Ltd., H2 2016 30 
Dormant Projects, H2 2016 46

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693278

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.